Drotrecogin alfa (activated) in adults with septic shock
DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency